CABOZANTINIB

cabozantinib 40 mg tablet, 30

CABOZANTINIB (15129G)

cabozantinib 40 mg tablet, 30
15129G
Body System:
Manner of administration:Oral
General Schedule
Authority Required (STREAMLINED)

Restriction  17611

Indication: Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET) or extra-pancreatic neuroendocrine tumour (epNET)
Treatment phase: Initial treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 30 # of repeats: 2 DPMQ: $9,472.93 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cabometyx